Cameron Reynolds

VolitionRX Ltd (NYSE: VNRX) stirred up some interest in the biotech community with blood tests that can predict colon cancer. What this means is that patients may no longer have to subject themselves to an invasive colonoscopy. In an exclusive interview with Benzinga, CEO Cameron Reynolds...

Uncomfortable and invasive colonoscopies might be a thing of the past with VolitionRX Ltd's (NYSE: VNRX) new cancer detection system. Through its research, VolitionRX developed a method for testing blood samples to detect various types of cancer, making diagnosis more accurate and reliable...